Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of onabotulinumtoxinA in high-frequency migraine
2017-002866-38Phase 2Active
- Sponsor
- IRCCS Mondino Foundation
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of botulinum toxin type A in migraine, sponsored by IRCCS Mondino Foundation. Primary endpoint: Reduction in monthly migraine days. Started Jun 2021; status: active.
02
Drugs
botulinum toxin type A
03
Conditions
migraine
Beyond the preview
Go deeper on 2017-002866-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002866-38.